They will do so using next-generation CRISPR/Cas9-based single-nucleotide correction technologies enabled by MaxCyte's cell engineering platform.
The collaboration will be with National Heart, Lung and Blood Institute, which is part of the NIH.
The two hope to "correct" the faulty haemoglobin gene that causes the disease and address DNA mutations that contribute to the disease.
As part of the tie-up, MaxCyte will supply messenger RNA molecules that convey genetic information from DNA to the ribosomes.
It will also use its Flow Electroporation Technology to develop reliable and effective processes to correct gene sequences.
MaxCyte chief executive Doug Doerfler said: "We believe that this work will further validate our platform for developing gene-editing therapies for a broad range of diseases while enabling rapid, development and commercial manufacturing of new therapies for patients where there is an extremely high unmet medical need."
In early morning trading, Maxcyte shares were up 1.6% at 249p.
-- Adds share price --